WINTON GROUP Ltd Increases Position in DexCom, Inc. $DXCM

WINTON GROUP Ltd raised its holdings in DexCom, Inc. (NASDAQ:DXCM) by 68.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 69,956 shares of the medical device company’s stock after acquiring an additional 28,474 shares during the period. WINTON GROUP Ltd’s holdings in DexCom were worth $6,106,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in DXCM. Natixis boosted its stake in DexCom by 217.5% during the second quarter. Natixis now owns 62,713 shares of the medical device company’s stock worth $5,474,000 after buying an additional 42,962 shares during the last quarter. California Public Employees Retirement System raised its holdings in shares of DexCom by 8.5% during the 2nd quarter. California Public Employees Retirement System now owns 494,414 shares of the medical device company’s stock worth $43,157,000 after acquiring an additional 38,714 shares during the period. Daner Wealth Management LLC acquired a new position in shares of DexCom during the 2nd quarter valued at about $213,000. Federated Hermes Inc. boosted its position in shares of DexCom by 82.1% during the 2nd quarter. Federated Hermes Inc. now owns 3,633,139 shares of the medical device company’s stock valued at $317,137,000 after acquiring an additional 1,638,407 shares during the last quarter. Finally, Gabelli Funds LLC grew its holdings in shares of DexCom by 0.6% in the second quarter. Gabelli Funds LLC now owns 50,300 shares of the medical device company’s stock valued at $4,391,000 after purchasing an additional 300 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Trading Up 0.4%

DXCM opened at $65.49 on Monday. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $93.25. The company has a quick ratio of 1.38, a current ratio of 1.56 and a debt-to-equity ratio of 0.45. The business has a fifty day simple moving average of $63.97 and a 200-day simple moving average of $75.00. The firm has a market cap of $25.54 billion, a P/E ratio of 36.38, a P/E/G ratio of 1.40 and a beta of 1.51.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.04. The firm had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. DexCom had a return on equity of 30.65% and a net margin of 15.96%.DexCom’s revenue was up 21.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.45 EPS. On average, equities analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on DXCM. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $84.00 target price on shares of DexCom in a research note on Monday, November 3rd. Piper Sandler set a $75.00 price target on shares of DexCom and gave the company a “buy” rating in a research report on Friday, October 31st. Canaccord Genuity Group set a $99.00 price objective on DexCom and gave the stock a “buy” rating in a research report on Friday, October 31st. Wall Street Zen cut DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 16th. Finally, Oppenheimer lowered DexCom from an “outperform” rating to a “market perform” rating in a research note on Monday, September 8th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.27.

Insider Activity

In related news, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the completion of the transaction, the director owned 27,031 shares in the company, valued at approximately $1,569,690.17. The trade was a 3.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Richard Alexander Collins sold 3,948 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $55.17, for a total transaction of $217,811.16. Following the sale, the director directly owned 37,994 shares in the company, valued at approximately $2,096,128.98. The trade was a 9.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 7,866 shares of company stock valued at $448,177. 0.32% of the stock is currently owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.